Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Uniq Biotech Ltd. is currently managing 2 pending office actions within the Chemistry & Materials technology area. These actions are assigned to 2 distinct examiners, which means each pending matter is being reviewed by a different individual. The portfolio is also distributed across 2 distinct art units, suggesting that the 2 pending office actions involve different specialized chemical or material processes.
The busiest examiner, HYUN, PAUL SANG HWA, is responsible for 1 pending office action. Given that there are 2 pending actions in total, the workload is split equally between the 2 distinct examiners. This distribution requires the company to navigate two different sets of examiner preferences while also adhering to the specific guidelines of 2 distinct art units.
With 2 distinct art units involved, the technical scrutiny for the 2 pending office actions will likely vary. The fact that 2 distinct examiners are each handling 1 pending action means there is no single point of contact for the entire portfolio. Practitioners must develop separate prosecution strategies to address the unique requirements of each examiner and art unit to resolve the 2 pending actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §102 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HYUN, PAUL SANG HWA | 1 | 69.8% | +36.3% |
| NGUYEN, BAO THUY L | 1 | 41.8% | +22.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18592264 | SAMPLE PROCESSING DEVICE | HYUN, PAUL SANG HWA | — |
| 18319302 | ASSAY SYSTEM FOR MULTIPLE ANALYTES | NGUYEN, BAO THUY L | — |
| Art Unit | Apps |
|---|---|
| 1796 | 1 |
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18592264 | SAMPLE PROCESSING DEVICE | HYUN, PAUL SANG HWA | 1796 | §102 | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18319302 | ASSAY SYSTEM FOR MULTIPLE ANALYTES | NGUYEN, BAO THUY L | 1677 | §103 | Non-Final OA | — | Pending | May 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniq Biotech Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Paul Sang Hwa Hyun has the most, with 1 of Uniq Biotech Ltd.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
